Lilly to buy ImClone

Share this article:

Lilly has announced plans to acquire ImClone for $6.5 billion.

The move follows months of bickering between ImClone and Bristol-Myers Squibb (BMS) regarding the appraisal value, the potential of ImClone's pipeline and, in early September, the emergence of a secret bidder.

BMS, which owns 16.6% of ImClone, had initially offered to buy the remainder of ImClone for $60 a share, valuing the company at $4.5 billion. That bid was rejected, and BMS returned to the table with a $4.7 billion dollar offer, upping the share price to $62. Imclone rejected that bid as well, citing a mystery bidder prepared to offer $70 a share, pending due diligence.

Lilly turned out to be the mystery bidder, and successfully entered into a definitive merger with ImClone on October 6. Erbitux, ImClone's billion dollar cancer treatment, will continue to be co-marketed by ImClone and BMS in the US.

“We think very highly of ImClone's groundbreaking work in oncology, particularly its success with Erbitux…and its ability to advance promising biotech molecules in its pipeline,” said John Lechleiter, president and CEO of Lilly, in a statement.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...